axicabtagene ciloleucel,cyclophosphamide,fludarabine
gilead,daiichi sankyo
['alycante', 'axi-cel', 'lymphoma', 'lymsm']
congress|#17icml presents results from the alycante trial investigating axi-cel as 2nd line therapy for treatment of lbcl. cmr at 3 months was 71% vs 12% expected with soc. or and cr rates were 91.1% and 82.3%, respectively #lymphoma #lymsm #lymphoma 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm